Quantcast
Last updated on April 16, 2014 at 13:39 EDT

Monsanto Announces Third Quarter Financial Results in Line with Expectations, Introduces 2011 Guidance Measures

June 30, 2010

ST. LOUIS, June 30, 2010 /PRNewswire-FirstCall/ — Monsanto Company (NYSE: MON) today announced its third-quarter financial results and highlighted some of the actions in progress to generate expected annual earnings growth percentages in the mid-teens. With its earnings results for the quarter and year-to-date in line with adjustments the company announced last month, company executives said the business is strong and well-positioned for future growth.


    ($ in millions)                      Third      Third     Nine     Nine
    ---------------                    Quarter    Quarter   Months   Months
                                          2010       2009    2010    2009
                                          ----       ----    ----    ----
    Net Sales by Segment
       Corn seed and traits             $1,020     $1,020  $3,836  $3,726
       Soybean seed and traits             549        540   1,383   1,367
       Cotton seed and traits              420        333     513     413
       Vegetable seeds                     204        206     600     572
       All other crops seeds and
        traits                             169        149     309     311
                                           ---        ---     ---     ---
    TOTAL Seeds and Genomics            $2,362     $2,248  $6,641  $6,389

       Roundup and other glyphosate-
        based herbicides                  $269       $614  $1,243  $2,749
       All other agricultural
        productivity products              331        299     665     707
                                           ---        ---     ---     ---
    TOTAL Agricultural
     Productivity                         $600       $913  $1,908  $3,456

    TOTAL Net Sales                     $2,962     $3,161  $8,549  $9,845
    ---------------                     ------     ------  ------  ------

    Gross Profit                        $1,387     $1,834  $4,225  $5,905
    ------------                        ------     ------  ------  ------

    Operating Expenses                    $828       $799  $2,426  $2,550
    ------------------                     ---        ---  ------  ------

    Interest Expense  - Net                $17        $18     $72     $24
    Other Expense (Income) - Net            $7         $4     $(3)    $62

    Net Income Attributable to
     Monsanto Company                     $384       $694  $1,252  $2,342
    --------------------------             ---        ---  ------  ------

    Diluted Earnings per Share           $0.70      $1.25   $2.27   $4.21
    --------------------------           -----      -----   -----   -----
    Items Affecting Comparability
     - EPS Impact
       Income on Discontinued
        Operations                   $       -  $       -  $(0.01) $(0.02)
       Acquired In-Process R&D (Aly
        Participacoes Ltda.)                 -          -       -    0.19
       Restructuring                      0.11          -    0.23       -
    Diluted Earnings per Share
     from Ongoing Business (For
     the definition of ongoing
     EPS, see note 1.)                   $0.81      $1.25   $2.49   $4.38
    ---------------------------          -----      -----   -----   -----
    Effective Tax Rate
     (Continuing Operations)                26%        30%     27%     28%
    ------------------------               ---        ---     ---     ---


                                        Third     Third     Nine     Nine
    Comparison as a Percent of        Quarter   Quarter   Months   Months
     Net Sales:                          2010      2009     2010     2009
    --------------------------       --------  --------  -------  -------
       Gross profit                        47%       58%      49%      60%
       Selling, general and
        administrative expenses
        (SG&A)                             17%       16%      18%      16%
       Research and development
        expenses (excluding acquired
        in-process R&D)                    10%        9%      10%       8%
       Income from continuing
        operations before income
        taxes                              18%       32%      20%      33%
       Net Income Attributable to
        Monsanto Company                   13%       22%      15%      24%
       --------------------------         ---       ---      ---      ---

“We’ve made some real changes to our portfolio and business approach, and the positive feedback I’m hearing from our customers tells me we are on the right track,” said Hugh Grant, chairman, president and chief executive officer for Monsanto. “We have demonstrated agility in the face of adversity, enhancing our portfolio and equipping our sales team with an unprecedented amount of product choices and price points to offer our customers. We’ve repositioned our Roundup® business to recognize its appropriate role in supporting our Seeds and Genomics segment. And we’ve demonstrated an ability to leverage our operational savings and sustain a strategic investment in research and development. This year has brought its challenges, yet we are quickly evolving into a newer, leaner, stronger Monsanto, well-positioned to meet our objective for mid-teens earnings growth driven by our seeds and traits business.”

Results of Operations

Price decreases for Roundup® and other glyphosate-based herbicides affected the company’s results as expected, despite the volume growth achieved for these products. Net sales decreased $199 million, or 6 percent, in the three-month comparison and $1.3 billion, or 13 percent, year to date. Net income in the third quarter was $384 million.

Gross profit declined 24 percent in the quarter to $1.4 billion, also driven by the price decreases for Roundup® and other glyphosate-based herbicides. For the first nine months, gross profit is down 28 percent or $1.7 billion.

Operating expenses were flat overall, with a slight decrease for selling, general and administrative (SG&A) expenses for the three month comparison. R&D expenses increased slightly as the company continues to manage more projects in advanced pipeline phases. As a percent of net sales, SG&A expenses were 17 percent and R&D expenses were 10 percent. Restructuring expense for the quarter was $86 million. This included $52 million charged to cost-of-goods related to discontinued products worldwide.

Earnings per share (EPS) for the third quarter was $0.70 on an as-reported basis, and $0.81 on an ongoing basis. EPS for the first nine months of fiscal year 2010 was $2.27 on an as-reported basis, and $2.49 on an ongoing basis. (For a reconciliation of EPS to ongoing EPS see page 1).

Cash Flow

The company saw an expected increase in cash outflow for the quarter, attributed to the Roundup® business. For the first nine months of fiscal year 2010, cash flow required by operations was $538 million compared to a source of $443 million for the same period last year. Net cash required by investing activities for the first nine months of fiscal year 2010 was $614 million, as compared to $588 million for the same period of fiscal year 2009.

Net cash required by financing activities for the first nine months of 2010 was $323 million, compared to net cash required of $775 million for the same period of fiscal year 2009.

Free cash flow was a use of $1.15 billion for the first nine months of fiscal year 2010, compared to a use of $145 million for the first nine months of fiscal year 2009. (For a reconciliation of free cash flow, see note 1.)

                                Seeds and Genomics Segment Detail
                                ---------------------------------
    ($ in millions)                          Net Sales
    ---------------                          ---------
                                   Third     Third      Nine     Nine
                                 Quarter   Quarter    Months   Months
    Seeds and Genomics              2010      2009      2010     2009
    ------------------          --------  --------   -------  -------
    Corn seed and traits          $1,020    $1,020    $3,836   $3,726
    --------------------          ------    ------    ------   ------
    Soybean seed and traits          549       540     1,383    1,367
    -----------------------          ---       ---     -----    -----
    Cotton seed and traits           420       333       513      413
    ----------------------           ---       ---       ---      ---
    Vegetable seeds                  204       206       600      572
    ---------------                  ---       ---       ---      ---
    All other crops seeds and
     traits                          169       149       309      311
    -------------------------        ---       ---       ---      ---
    TOTAL Seeds and Genomics      $2,362    $2,248    $6,641   $6,389
    ------------------------      ------    ------    ------   ------


    ($ in millions)                          Gross Profit
    ---------------                          ------------
                                  Third     Third      Nine      Nine
                                Quarter   Quarter    Months    Months
    Seeds and Genomics             2010      2009      2010      2009
    ------------------         --------  --------   -------   -------
    Corn seed and traits           $570      $630    $2,294    $2,445
    --------------------           ----      ----    ------    ------
    Soybean seed and traits         292       338       817       856
    -----------------------         ---       ---       ---       ---
    Cotton seed and traits          328       249       376       296
    ----------------------          ---       ---       ---       ---
    Vegetable seeds                 112       113       362       308
    ---------------                 ---       ---       ---       ---
    All other crops seeds and
     traits                         104        97       166       177
    -------------------------       ---       ---       ---       ---
    TOTAL Seeds and Genomics     $1,406    $1,427    $4,015    $4,082
    ------------------------     ------    ------    ------    ------


                                     Earnings Before Interest & Taxes
    ($ in millions)                               (EBIT)
    ---------------                   --------------------------------
                                    Third      Third       Nine      Nine
                                  Quarter    Quarter     Months    Months
    Seeds and Genomics               2010       2009       2010      2009
    ------------------           --------   --------    -------   -------
    EBIT (For a reconciliation
     of EBIT, see note 1.)           $704       $804     $2,009    $2,081
    --------------------------       ----       ----     ------    ------
    Unusual Items Affecting
     EBIT
    -----------------------
       Restructuring                  $68       NONE       $130      NONE
       -------------                  ---       ----       ----      ----
       IPR&D resulting from
        acquisition of Aly
        Participacoes Ltda.          NONE       NONE       NONE      $162
       --------------------          ----       ----       ----      ----

The Seeds and Genomics segment consists of the company’s global seeds and related traits business, and biotechnology platforms.

For the quarter, sales in the segment have increased by 5 percent. In corn, approximately 33 million acres of its triple-stack and SmartStax(TM) products were planted in the United States, up from 31 million last year. More than 75 percent of the company’s branded corn portfolio in the United States is either a triple stack or Genuity® SmartStax(TM), which represents a step change improvement over last year. This complements growth in South America, where the increase in trait acres in Brazil and Argentina has had a positive overall mix effect on the business.

The company also cited progress with its Genuity® Roundup Ready 2 Yield® soybean, with more than 40 percent of its branded customers trying even more varieties this year. That next-generation soybean platform is gaining momentum as third parties, including new commercial licensees, continue to evaluate and choose Roundup Ready 2 Yield®.

Cotton and vegetables continue to track well with expectations, delivering volume and margin improvements to the seeds-and-traits portfolio.

In total, sales for Monsanto’s Seeds and Genomics segment in the third quarter of fiscal 2010 increased slightly over last year’s third quarter, consistent with company’s expectations. The company expects total gross profit for the segment to come in at a range of $4.6 to $4.7 billion for the year, an increase over 2009.

                              Agricultural Productivity Segment Detail
                              ----------------------------------------
    ($ in millions)                            Net Sales
    ---------------
                                  Third     Third      Nine      Nine
                                Quarter   Quarter    Months    Months
    Agricultural Productivity      2010      2009      2010      2009
    -------------------------  --------  --------   -------   -------
    Roundup and other
     glyphosate-based
     herbicides                    $269      $614    $1,243    $2,749
    All other agricultural          331       299       665       707
    productivity products
    TOTAL Agricultural
     Productivity                  $600      $913    $1,908    $3,456
    ------------------             ----      ----    ------    ------


    ($ in millions)                          Gross Profit
    ---------------
                                  Third     Third      Nine      Nine
                                Quarter   Quarter    Months    Months
    Agricultural Productivity      2010      2009      2010      2009
    -------------------------  --------  --------   -------   -------
    Roundup and other
     glyphosate-based
     herbicides                   $(189)     $273     $(103)   $1,514
    All other agricultural          170       134       313       309
    productivity products
    TOTAL Agricultural
     Productivity                  $(19)     $407      $210    $1,823
    ------------------             ----      ----      ----    ------


                                    Earnings Before Interest & Taxes
    ($ in millions)                              (EBIT)
    ---------------                 --------------------------------
                                  Third      Third      Nine      Nine
    Agricultural                Quarter    Quarter    Months    Months
     Productivity                  2010       2009      2010      2009
    ------------               --------   --------   -------   -------
    EBIT (For a
     reconciliation of EBIT,
     see note 1.)                 $(175)      $211     $(228)   $1,210
    ------------------------      -----       ----     -----    ------
    Unusual Items Affecting
     EBIT
    -----------------------
       Restructuring                $18     NONE         $54    NONE
       -------------                ---     ----         ---    ----
       EBIT from Discontinued
        Operations               NONE       NONE          $5       $19
       ----------------------    ----       ----         ---       ---

The Agricultural Productivity segment consists of the crop protection products and lawn-and-garden herbicide products. Sales in the third quarter of fiscal 2010 for Monsanto’s Agricultural Productivity segment declined 34 percent or $313 million compared with the same period last year. Gross profit was a loss of $189 million in the quarter for Roundup® and other glyphosate-based herbicides, reflecting the impact associated with the repositioning of the Roundup® business.

For the third quarter, the company released strong results from the Other Agricultural Productivity part of this segment, reflecting a record year in the lawn-and-garden business. For the fiscal year, the segment is expected to deliver approximately $450 million to $600 million in gross profit, which includes a Roundup® contribution of between $50 and $200 million after the repositioning actions.

Outlook

Monsanto affirmed its cash flow and EPS guidance and provided preliminary financial guidance for fiscal year 2011. The company expects free cash flow for fiscal year 2010 will be in the range of $400 million to $500 million including the after-tax cash effect from a restructuring charge. Net cash provided by operating activities is expected to be $1.3 billion to $1.5 billion, and net cash required by investing activities is expected to be approximately $900 million to $1 billion for fiscal year 2010. (For a reconciliation of free cash flow, see note 1.)

The company expects fiscal-year 2010 earnings per share to be in the range of $2.40 to $2.60 on an ongoing basis and $2.15 to $2.41 on an as-reported basis. (For a reconciliation of EPS, see note 1.)

SG&A expenses continued to track below expectations and are expected to represent approximately $2 billion to $2.1 billion for the year.

Sharing the first view of fiscal year 2011 since the company’s repositioning of its Roundup® business last month, the company outlined the key metrics that will enable it to meet its objective of achieving earnings growth in the mid-teen percentages going forward. Monsanto’s growth is expected to come exclusively from the Seeds and Genomics segment, where the company expects gross profit growth in the double digits. The company expects top-line growth from an increase in unit volume as well as mix improvement as Monsanto expands the availability of its new products.

Central to that strategy is U.S. corn, where Monsanto will offer more products at more price points. South America corn is also a key driver, as the company is poised to increase penetration of its first-generation double-stack corn in Argentina, which will serve as building block for the technology progression that’s already under way in the United States. The same is true for Brazil, where stacked traits will create new opportunities for farmers as the company prepares to introduce its second-generation Corn Borer technology. In soybeans, Monsanto is confident that as its pricing approach enables more farmers to experience the benefits of Genuity® Roundup Ready 2 Yield® and see it perform on farm, it will enable the company to win new customers.

The company’s R&D pipeline fuels the growth expected from seeds and traits, and Monsanto plans to resource that pipeline for success as it continues to support a higher number of projects in the more costly later stages of development. To reinforce this commitment, executives said Monsanto will move to providing a range for R&D spend annually rather than a metric that adjusts with sales. The range for 2011 is expected to represent an increase over the 2010 endpoint, but at a rate somewhat below the growth over the past few years.

The company expects gross profit for its Agricultural Productivity Segment at $550 million to $600 million in fiscal year 2011. Operational leverage is expected to be a key contributor to the earnings growth targets, and executives pointed to an institutionalized cost discipline that allows SG&A spend to hold at inflation-level growth.

Webcast Information

In conjunction with this announcement, Monsanto will hold a conference call at 8:30 a.m. central time (9:30 a.m. eastern time) today. The call will focus on these results and may include a discussion of Monsanto’s strategic initiatives and other matters related to the company’s business.

Presentation slides and a simultaneous audio webcast of the conference call may be accessed by visiting the company’s web site at www.monsanto.com and clicking on “Investor Information.” Visitors may need to download Windows Media Player(TM) prior to listening to the webcast. Following the live broadcast, a replay of the webcast will be available on the Monsanto Web site for three weeks.

About Monsanto Company

Monsanto Company is a leading global provider of technology-based solutions and agricultural products that improve farm productivity and food quality. Monsanto remains focused on enabling both small-holder and large-scale farmers to produce more from their land while conserving more of our world’s natural resources such as water and energy. To learn more about our business and our commitments, please visit: www.monsanto.com. Follow our business on Twitter® at www.twitter.com/MonsantoCo, on the company blog, Beyond the Rows at www.monsantoblog.com, or subscribe to our News Release RSS Feed.

Cautionary Statements Regarding Forward-Looking Information:

Certain statements contained in this release are “forward-looking statements,” such as statements concerning the company’s anticipated financial results, current and future product performance, regulatory approvals, business and financial plans and other non-historical facts. These statements are based on current expectations and currently available information. However, since these statements are based on factors that involve risks and uncertainties, the company’s actual performance and results may differ materially from those described or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, among others: continued competition in seeds, traits and agricultural chemicals; the company’s exposure to various contingencies, including those related to intellectual property protection, regulatory compliance and the speed with which approvals are received, and public acceptance of biotechnology products; the success of the company’s research and development activities; the outcomes of major lawsuits; developments related to foreign currencies and economies; successful operation of recent acquisitions; fluctuations in commodity prices; compliance with regulations affecting our manufacturing; the accuracy of the company’s estimates related to distribution inventory levels; the company’s ability to fund its short-term financing needs and to obtain payment for the products that it sells; the effect of weather conditions, natural disasters and accidents on the agriculture business or the company’s facilities; and other risks and factors detailed in the company’s most recent Form 10-K Report to the SEC. Undue reliance should not be placed on these forward-looking statements, which are current only as of the date of this release. The company disclaims any current intention or obligation to update any forward-looking statements or any of the factors that may affect actual results.

Notes to editors: Roundup, Genuity, SmartStax and Roundup Ready 2 Yield are trademarks of Monsanto Company and its wholly-owned subsidiaries.

References to Roundup herbicides in this release mean Roundup-branded herbicides, excluding lawn-and-garden herbicide products.

                                       Monsanto Company
                                Selected Financial Information
                        (Dollars in millions, except per share amounts)
                                           Unaudited
    Statements
     of
     Consolidated
     Operations        Three Months  Three Months  Nine Months   Nine Months
    -------------      ------------  ------------  -----------   -----------
                           Ended         Ended         Ended         Ended
                           -----         -----         -----         -----
                       May 31, 2010  May 31, 2009  May 31, 2010  May 31, 2009
                       ------------  ------------  ------------  ------------
    Net Sales                $2,962        $3,161        $8,549        $9,845
    Cost of
     Goods Sold               1,575         1,327         4,324         3,940
                              -----         -----         -----         -----
    Gross Profit              1,387         1,834         4,225         5,905
    Operating
     Expenses:
       Selling,
        General and
        Administrative
        Expenses                492           504         1,500         1,576
       Research and
        Development
        Expenses                302           295           848           812
       Acquired In-
        Process
        Research
        and
        Development               -             -             -           162
        Restructuring
        Charges,
        Net                      34             -            78             -
    Total
     Operating
     Expenses                   828           799         2,426         2,550
    Income From
     Operations                 559         1,035         1,799         3,355
    Interest
     Expense                     35            32           115            81
    Interest
     Income                     (18)          (14)          (43)          (57)
    Other
     Expense
     (Income) -
     Net                          7             4            (3)           62
                                ---           ---           ---           ---
    Income from
     Continuing
     Operations
     Before
     Income
     Taxes                      535         1,013         1,730         3,269
    Income Tax
     Provision                  138           308           468           924
    Income from
     Continuing
     Operations
     Including
     Portion
     Attributable
     to
     Noncontrolling
     Interest                   397           705         1,262         2,345
    Discontinued
     Operations:
       Income From
        Operations
        of
        Discontinued
        Businesses                -             -             5            19
       Income Tax
        Provision                 -             -             -             8
                                ---           ---           ---           ---
    Income on
     Discontinued
     Operations                   -             -             5            11

    Net Income                 $397          $705        $1,267        $2,356
                               ====          ====        ======        ======
    Less: Net
     Income
     Attributable
     to
     Noncontrolling
     Interest                    13            11            15            14
                                ===           ===           ===           ===
    Net Income
     Attributable
     to Monsanto
     Company                   $384          $694        $1,252        $2,342
                               ====          ====        ======        ======
    EBIT (See
     note 1)                   $529        $1,015        $1,781        $3,291
                               ====        ======        ======        ======
    Basic
     Earnings
     per Share:
    Income From
     Continuing
     Operations               $0.71         $1.27         $2.29         $4.26
    Income on
     Discontinued
     Operations                   -             -           .01          0.02
    Net Income                $0.71         $1.27         $2.30         $4.28
                              =====         =====         =====         =====

    Diluted
     Earnings
     per Share:
    Income From
     Continuing
     Operations               $0.70         $1.25         $2.26         $4.19
    Income on
     Discontinued
     Operations                   -             -           .01          0.02
    Net Income                $0.70         $1.25         $2.27         $4.21
                              =====         =====         =====         =====

    Weighted
     Average
     Shares
     Outstanding:
         Basic                543.2         546.4         544.7         547.5
         Diluted              549.9         554.6         552.1         555.9
         -------              -----         -----         -----         -----

                                Monsanto Company
                         Selected Financial Information
                              (Dollars in millions)
                                    Unaudited

    Condensed Statements of Consolidated Financial
     Position                                           As of       As of
    ----------------------------------------------      -----       -----
                                                                   Aug. 31,
                                                    May 31, 2010     2009
                                                    ------------  ---------
    Assets
    Current Assets:
        Cash and Cash Equivalents                           $475      $1,956
        Trade Receivables, Net                             3,233       1,556
        Miscellaneous Receivables                            710         654
        Deferred Tax Assets                                  552         662
        Inventory, Net                                     2,847       2,934
        Other Current Assets                                  83         121
                                                             ---         ---
    Total Current Assets                                   7,900       7,883

    Property, Plant and Equipment, Net                     4,103       3,609
    Goodwill                                               3,184       3,218
    Other Intangible Assets, Net                           1,262       1,371
    Noncurrent Deferred Tax Assets                           858         743
    Long-Term Receivables, Net                               473         557
    Other Assets                                             558         496
                                                             ---         ---
    Total Assets                                         $18,338     $17,877
                                                         =======     =======

    Liabilities and Shareowners' Equity
    Current Liabilities:
      Short-Term Debt, Including Current Portion of
       Long-Term Debt                                       $839         $79
      Accounts Payable                                       573         676
      Income Taxes Payable                                   147          79
      Accrued Compensation and Benefits                      197         263
      Accrued Marketing Programs                             708         934
      Deferred Revenues                                      201         219
      Grower Production Accruals                             146         139
      Dividends Payable                                        -         145
      Customer Payable                                         -         307
      Restructuring Reserves                                 177         286
      Miscellaneous Short-Term Accruals                      717         629
                                                             ---         ---
    Total Current Liabilities                              3,705       3,756

    Long-Term Debt                                         1,862       1,724
    Postretirement Liabilities                               722         793
    Long-Term Deferred Revenue                               422         488
    Noncurrent Deferred Tax Liabilities                      134         153
    Long-Term Portion of Environmental and
     Litigation Reserves                                     189         197
    Other Liabilities                                        687         641
    Monsanto Shareowners' Equity                          10,574      10,056
    Noncontrolling Interest                                   43          69
                                                             ---         ---
    Total Shareowners' Equity                             10,617      10,125
                                                          ======      ======
    Total Liabilities and Shareowners' Equity            $18,338     $17,877
                                                         =======     =======

    Debt to Capital Ratio:                                    20%         15%
    ----------------------                                   ---         ---

                                 Monsanto Company
                          Selected Financial Information
                              (Dollars in millions)
                                    Unaudited

                                               Nine Months   Nine Months
    Statements of Consolidated Cash Flows         Ended         Ended
    -------------------------------------      -----------   -----------
                                              May 31, 2010  May 31, 2009
                                              ------------  ------------
    Operating Activities:
      Net Income                                    $1,267        $2,356
      Adjustments to Reconcile Cash Provided
       by Operating Activities:
      Items That Did Not Require (Provide)
       Cash:
       Depreciation and Amortization                   446           404
       Bad-Debt Expense                                 41            56
       Stock-Based Compensation Expense                 72            86
       Excess Tax Benefits from Stock-Based
        Compensation                                   (40)          (24)
       Deferred Income Taxes                           (98)           12
       Restructuring Charges, Net                       78             -
       Equity Affiliate Income, Net                    (21)          (11)
       Acquired In-Process Research and
        Development                                      -           162
       Net Gain on Sales of a Business or
        Other Assets                                    (2)           (6)
       Other Items                                      38           (58)
      Changes in Assets and Liabilities that
       Provided (Required) Cash, Net of
       Acquisitions:
       Trade Receivables, Net                       (1,648)         (967)
       Inventory, Net                                   78          (853)
       Deferred Revenues                               (80)         (666)
       Accounts Payable and Other Accrued
        Liabilities                                   (324)          (40)
       Restructuring Cash Payments                    (175)            -
       Pension Contributions                           (95)          (51)
       Net Investment Hedge Settlement                  (4)           36
       Other Items                                     (71)            7
    Net Cash Provided (Required) by
     Operating Activities                             (538)          443
    -------------------------------                   ----           ---

    Cash Flows Provided (Required) by
     Investing Activities:
      Maturities of Short-Term Investments               -           117
      Capital Expenditures                            (560)         (661)
      Acquisitions of Businesses, Net of Cash
       Acquired                                        (57)         (280)
      Purchases of Long-Term Equity
       Securities                                      (14)           (7)
      Technology and Other Investments                 (26)          (60)
      Proceeds from Divestiture of a Business            -           300
      Other Investments and Property Disposal
       Proceeds                                         43             3
    Net Cash Required by Investing
     Activities                                       (614)         (588)
    ------------------------------                    ----          ----

    Cash Flows Provided (Required) by
     Financing Activities:
      Net Change in Financing With Less Than
       90-Day Maturities                               596           (44)
      Short-Term Debt Proceeds                          26            55
      Short-Term Debt Reductions                       (54)          (45)
      Long-Term Debt Reductions                         (3)          (70)
      Payments on Other Financing                       (3)            -
      Treasury Stock Purchases                        (498)         (310)
      Stock Option Exercises                            50            30
      Excess Tax Benefits from Stock-Based
       Compensation                                     40            24
      Dividend Payments                               (434)         (408)
      Dividend Payments to Noncontrolling
       Interests                                       (43)           (7)
      -----------------------------------              ---           ---
    Net Cash Required by Financing
     Activities                                       (323)         (775)
    ------------------------------                    ----          ----
    Effect of Exchange Rate Changes on Cash
     and Cash Equivalents                               (6)         (114)
    Net Decrease in Cash and Cash
     Equivalents                                    (1,481)       (1,034)
    Cash and Cash Equivalents at Beginning
     of Period                                       1,956         1,613
    --------------------------------------           -----         -----
    Cash and Cash Equivalents at End of
     Period                                           $475          $579
    -----------------------------------               ----          ----


                                 Monsanto Company
                          Selected Financial Information
                               (Dollars in millions)
                                     Unaudited

1. EBIT, Ongoing EPS and Free Cash Flow: The presentations of EBIT, ongoing EPS and free cash flow are not intended to replace net income (loss), cash flows, financial position or comprehensive income (loss), and they are not measures of financial performance as determined in accordance with generally accepted accounting principles (GAAP) in the United States. The following tables reconcile EBIT, ongoing EPS and free cash flow to the respective most directly comparable financial measure calculated in accordance with GAAP.

Reconciliation of EBIT to Net Income (Loss): EBIT is defined as earnings (loss) before interest and taxes. Earnings (loss) is intended to mean net income (loss) as presented in the Statements of Consolidated Operations under GAAP. The following table reconciles EBIT to the most directly comparable financial measure, which is net income (loss).


                                            Three Months         Nine Months
                                                   Ended               Ended
                                            ------------        -----------
                                         May
                                         31,   May 31,  May 31,  May 31,
                                        2010      2009     2010     2009
                                        ----      ----     ----     ----
    EBIT - Seeds and Genomics
     Segment                            $704      $804   $2,009   $2,081
    EBIT - Agricultural Productivity
     Segment                            (175)      211     (228)   1,210
                                        ----       ---     ----    -----
    EBIT- Total                          529     1,015    1,781    3,291
    Interest Expense - Net                17        18       72       24
    Income Tax Provision (A)             128       303      457      925
    Net Income Attributable to
     Monsanto Company                   $384      $694   $1,252   $2,342
    --------------------------          ----      ----   ------   ------
    (A)  Includes the income tax provision from continuing operations,
    the income tax provision on noncontrolling interests, and the income
    tax provision on discontinued operations.

Reconciliation of EPS to Ongoing EPS: Ongoing EPS is calculated excluding certain after-tax items which Monsanto does not consider part of ongoing operations.


                                             Fourth
                                Fiscal       Quarter        Nine months
                                Year 2010    2010           ended
                                ---------   -------         -----------
                               Guidance     Guidance       May 31, 2010
                               --------     --------       ------------
    Diluted Earnings per Share  $2.15-$2.41  $(0.11)-$0.09        $2.27
    Restructuring Charges       $0.19-$0.25          $0.02        $0.23
    Income on Discontinued
     Operations                           -              -       $(0.01)
    Diluted Earnings per Share
     from Ongoing Business      $2.40-$2.60  $(0.09)-$0.11        $2.49
    --------------------------  -----------  -------------        -----

Reconciliation of Free Cash Flow: Free cash flow represents the total of cash flows from operating activities and investing activities, as reflected in the Statements of Consolidated Cash Flows presented in this release. With respect to the fiscal year 2010 free cash flow target, Monsanto does not include any estimates or projections of Net Cash Provided (Required) by Financing Activities because in order to prepare any such estimate or projection, Monsanto would need to rely on market factors and conditions that are outside of its control.


                                   Fiscal Year    Nine Months Ended
                                   -----------    -----------------
                                       2010           May 31,
                                       ----          -------
                                     Guidance
                                     --------
                                                  2010       2009
                                                  ----       ----
    Net Cash (Required)
     Provided by Operating
     Activities               $     1,300-1,500   $(538)      $443
    Net Cash (Required)
     Provided by Investing
     Activities                   (900)-(1,000)    (614)      (588)
                                  -------------    ----       ----
    Free Cash Flow            $         400-500 $(1,152)     $(145)
    Net Cash Provided
     (Required) by Financing
     Activities                             N/A    (323)      (775)
    Effect of Exchange Rate
     Changes on Cash and Cash
      Equivalents                                    (6)      (114)
                                                    ---       ----
                                            N/A
                                             --
    Net Decrease in Cash and
     Cash Equivalents                       N/A $(1,481)   $(1,034)
    Cash and Cash Equivalents
     at Beginning of Period                 N/A  $1,956     $1,613
                                            ---  ------     ------
    Cash and Cash Equivalents
     at End of Period                       N/A    $475       $579
    -------------------------               ===    ====       ====


    CONTACT       Media:      Kelli Powers  (314-694-4003)
                  Analysts:   Bryan Hurley (314-694-8148)

SOURCE Monsanto Company


Source: newswire